BioNTech SE Share Price Today: Live Updates & Key Insights

BioNTech SE share price today is $89.19, up -0.04%. The stock opened at $88.685 against the previous close of $89.31, with an intraday high of $89.56 and low of $87.27.

BioNTech SE Share Price Chart

BioNTech SE

us-stock
To Invest in {{usstockname}}
us-stock

BioNTech SE Share Price Performance

$89.19 -0.0004(-0.04%) BNTX at 23 Mar 2026 12:16 PM Biotechnology
Lowest Today 87.27
Highest Today 89.56
Today’s Open 88.685
Prev. Close 89.31
52 Week High 124.00
52 Week Low 79.52
Day’s Range: Low 87.27 High 89.56
52-Week Range: Low 79.52 High 124.00
1 day return -
1 Week return -1.35
1 month return -18.78
3 month return -3.13
6 month return -9.54
1 year return -11.33
3 year return -33.25
5 year return -15.54
10 year return -

BioNTech SE Institutional Holdings

FMR Inc 2.36

T. Rowe Price Investment Management,Inc. 1.92

Flossbach von Storch AG 1.67

PRIMECAP Management Company 1.51

Dodge & Cox 1.44

FvS SICAV Multiple Opportunities F 1.08

Dodge & Cox International Stock I 1.00

Vanguard Capital Opportunity Inv 0.87

Pfizer Inc 0.66

BNP Paribas Arbitrage, SA 0.63

Temasek Holdings Ltd. 0.60

T. Rowe Price Capital Appreciation 0.57

Jane Street Group LLC 0.54

Baillie Gifford & Co Limited. 0.50

Fidelity Contrafund 0.49

FvS Multiple Opportunities II I 0.46

Capital Research & Mgmt Co - Division 3 0.45

T. Rowe Price US Mid-Cap Growth Equity 0.41

T. Rowe Price Mid-Cap Growth 0.41

PRIMECAP Odyssey Aggressive Growth 0.37

First Trust NYSE Arca Biotech ETF 0.32

BlackRock Inc 0.30

Franklin Resources Inc 0.29

Fidelity Growth Compy Commingled Pl S 0.28

Citadel Advisors Llc 0.27

UBS Group AG 0.24

Candriam Luxembourg S.C.A. 0.24

Morgan Stanley - Brokerage Accounts 0.24

Deka-GlobalChampions CF 0.24

Invesco Emerging Markets Equity 0.23

Bank of America Corp 0.23

Bank of New York Mellon Corp 0.23

American Funds IS® Growth 1 0.22

Capital Group Growth Composite 0.22

Fidelity Growth Company Fund 0.21

Dodge & Cox Global Stock I 0.21

iShares Biotechnology ETF 0.20

Long Focus Capital Management, LLC 0.20

American Funds EUPAC A 0.19

Capital Group EUPAC Composite 0.19

BioNTech SE Market Status

Strong Buy: 13

Buy: 3

Hold: 5

Sell: 0

Strong Sell: 0

BioNTech SE Fundamentals

Market Cap 22435.81 M

PB Ratio 1.0119

PE Ratio 0.0

Enterprise Value 5698.21 M

Total Assets 21979.24 M

Volume 1573370

BioNTech SE Company Financials

Annual Revenue FY23:6618300000 6618.3M, FY22:17310600000 17310.6M, FY21:18976700000 18976.7M, FY20:482325000 482.3M, FY19:108589000 108.6M

Annual Profit FY23:4299000000 4299.0M, FY22:12778600000 12778.6M, FY21:15116000000 15116.0M, FY20:-222037000 -222.0M, FY19:-135238000 -135.2M

Annual Net worth FY23:2751100000 2751.1M, FY22:9434400000 9434.4M, FY21:10292500000 10292.5M, FY20:15198000 15.2M, FY19:-179172000 -179.2M

Quarterly Revenue Q3/2025:1518900000 1518.9M, Q2/2025:260800000 260.8M, Q1/2025:182800000 182.8M, Q3/2024:1244800000 1244.8M, Q2/2024:128700000 128.7M

Quarterly Profit Q3/2025:1370600000 1370.6M, Q2/2025:184400000 184.4M, Q1/2025:99000000 99.0M, Q3/2024:1065900000 1065.9M, Q2/2024:68900000 68.9M

Quarterly Net worth Q3/2025:-28700000 -28.7M, Q2/2025:-386600000 -386.6M, Q1/2025:-415800000 -415.8M, Q3/2024:198100000 198.1M, Q2/2024:-807800000 -807.8M

About BioNTech SE & investment objective

Company Information BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

Organisation Biotechnology

Employees 7807

Industry Biotechnology

CEO Dr. Ugur Sahin M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

BioNTech SE FAQs

What is the share price of BioNTech SE today?

The current share price of BioNTech SE is $89.19.

Can I buy BioNTech SE shares in India?

Yes, Indian investors can buy BioNTech SE shares by opening an international trading and demat account with Motilal Oswal.

How to buy BioNTech SE shares in India?

You can easily invest in BioNTech SE shares from India by:

Can I buy fractional shares of BioNTech SE?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of BioNTech SE?

BioNTech SE has a market cap of $22435.81 M.

In which sector does BioNTech SE belong?

BioNTech SE operates in the Biotechnology sector.

What documents are required to invest in BioNTech SE stocks?

To invest, you typically need:

What is the PE and PB ratio of BioNTech SE?

The PE ratio of BioNTech SE is N/A and the PB ratio is 1.01.